Synjardy

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
27-09-2023
Produktens egenskaper Produktens egenskaper (SPC)
27-09-2023

Aktiva substanser:

empagliflozin, metformin

Tillgänglig från:

Boehringer Ingelheim

ATC-kod:

A10BD20

INN (International namn):

empagliflozin, metformin

Terapeutisk grupp:

Drugs used in diabetes

Terapiområde:

Diabetes Mellitus, Type 2

Terapeutiska indikationer:

Synjardy is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients inadequately controlled on their maximally tolerated dose of metformin alone;in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin;in patients already being treated with the combination of empagliflozin and metformin as separate tablets.

Produktsammanfattning:

Revision: 26

Bemyndigande status:

Authorised

Tillstånd datum:

2015-05-27

Bipacksedel

                                66
B. PACKAGE LEAFLET
67
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
SYNJARDY 5 MG/850 MG FILM-COATED TABLETS
SYNJARDY 5 MG/1,000 MG FILM-COATED TABLETS
SYNJARDY 12.5 MG/850 MG FILM-COATED TABLETS
SYNJARDY 12.5 MG/1,000 MG FILM-COATED TABLETS
empagliflozin/metformin hydrochloride
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Synjardy is and what it is used for
2.
What you need to know before you take Synjardy
3.
How to take Synjardy
4.
Possible side effects
5.
How to store Synjardy
6.
Contents of the pack and other information
1.
WHAT SYNJARDY IS AND WHAT IT IS USED FOR
WHAT SYNJARDY IS
Synjardy contains two active substances empagliflozin and metformin.
Each belongs to a group of
medicines called “oral anti-diabetics”. These are medicines taken
by mouth to treat type 2 diabetes.
WHAT IS TYPE 2 DIABETES?
Type 2 diabetes is a disease that comes from both your genes and your
lifestyle. If you have type 2
diabetes, your pancreas does not make enough insulin to control the
level of glucose in your blood,
and your body is unable to use its own insulin effectively. This
results in high levels of glucose in your
blood which can lead to medical problems like heart disease, kidney
disease, blindness, and poor
circulation in your limbs.
HOW SYNJARDY WORKS
Empagliflozin belongs to a group of medicines called sodium glucose
co-transporter-2 (SGLT2)
inhibitors. It works by blocking the SGLT2 protein in your kidneys.
This causes blood sugar (glucose)
to be removed in your urine. Metformin
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Synjardy 5 mg/850 mg film-coated tablets
Synjardy 5 mg/1,000 mg film-coated tablets
Synjardy 12.5 mg/850 mg film-coated tablets
Synjardy 12.5 mg/1,000 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Synjardy 5 mg/850 mg film-coated tablets
Each tablet contains 5 mg empagliflozin and 850 mg metformin
hydrochloride.
Synjardy 5 mg/1,000 mg film-coated tablets
Each tablet contains 5 mg empagliflozin and 1,000 mg metformin
hydrochloride.
Synjardy 12.5 mg/850 mg film-coated tablets
Each tablet contains 12.5 mg empagliflozin and 850 mg metformin
hydrochloride.
Synjardy 12.5 mg/1,000 mg film-coated tablets
Each tablet contains 12.5 mg empagliflozin and 1,000 mg metformin
hydrochloride.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
Synjardy 5 mg/850 mg film-coated tablets
Yellowish white, oval, biconvex film coated tablets debossed with
“S5” and the Boehringer Ingelheim
logo on one side and “850” on the other side (tablet length: 19.2
mm, tablet width: 9.4 mm).
Synjardy 5 mg/1,000 mg film-coated tablets
Brownish yellow, oval, biconvex film coated tablets debossed with
“S5” and the Boehringer
Ingelheim logo on one side and “1000” on the other side (tablet
length: 21.1 mm, tablet width:
9.7 mm).
Synjardy 12.5 mg/850 mg film-coated tablets
Pinkish white, oval, biconvex film coated tablets debossed with
“S12” and the Boehringer Ingelheim
logo on one side and “850” on the other side (tablet length: 19.2
mm, tablet width: 9.4 mm).
Synjardy 12.5 mg/1,000 mg film-coated tablets
Dark brownish purple, oval, biconvex film coated tablets debossed with
“S12” and the Boehringer
Ingelheim logo on one side and “1000” on the other side (tablet
length: 21.1 mm, tablet width:
9.7 mm).
3
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Synjardy is indicated for the treatment of adults with type 2 diabetes
mellitus as an adjunct to diet and
exercise:

i
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 27-09-2023
Produktens egenskaper Produktens egenskaper bulgariska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 05-07-2017
Bipacksedel Bipacksedel spanska 27-09-2023
Produktens egenskaper Produktens egenskaper spanska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 05-07-2017
Bipacksedel Bipacksedel tjeckiska 27-09-2023
Produktens egenskaper Produktens egenskaper tjeckiska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 05-07-2017
Bipacksedel Bipacksedel danska 27-09-2023
Produktens egenskaper Produktens egenskaper danska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 05-07-2017
Bipacksedel Bipacksedel tyska 27-09-2023
Produktens egenskaper Produktens egenskaper tyska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 05-07-2017
Bipacksedel Bipacksedel estniska 27-09-2023
Produktens egenskaper Produktens egenskaper estniska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 05-07-2017
Bipacksedel Bipacksedel grekiska 27-09-2023
Produktens egenskaper Produktens egenskaper grekiska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 05-07-2017
Bipacksedel Bipacksedel franska 27-09-2023
Produktens egenskaper Produktens egenskaper franska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 05-07-2017
Bipacksedel Bipacksedel italienska 27-09-2023
Produktens egenskaper Produktens egenskaper italienska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 05-07-2017
Bipacksedel Bipacksedel lettiska 27-09-2023
Produktens egenskaper Produktens egenskaper lettiska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 05-07-2017
Bipacksedel Bipacksedel litauiska 27-09-2023
Produktens egenskaper Produktens egenskaper litauiska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 05-07-2017
Bipacksedel Bipacksedel ungerska 27-09-2023
Produktens egenskaper Produktens egenskaper ungerska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 05-07-2017
Bipacksedel Bipacksedel maltesiska 27-09-2023
Produktens egenskaper Produktens egenskaper maltesiska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 05-07-2017
Bipacksedel Bipacksedel nederländska 27-09-2023
Produktens egenskaper Produktens egenskaper nederländska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 05-07-2017
Bipacksedel Bipacksedel polska 27-09-2023
Produktens egenskaper Produktens egenskaper polska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 05-07-2017
Bipacksedel Bipacksedel portugisiska 27-09-2023
Produktens egenskaper Produktens egenskaper portugisiska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 05-07-2017
Bipacksedel Bipacksedel rumänska 27-09-2023
Produktens egenskaper Produktens egenskaper rumänska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 05-07-2017
Bipacksedel Bipacksedel slovakiska 27-09-2023
Produktens egenskaper Produktens egenskaper slovakiska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 05-07-2017
Bipacksedel Bipacksedel slovenska 27-09-2023
Produktens egenskaper Produktens egenskaper slovenska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 05-07-2017
Bipacksedel Bipacksedel finska 27-09-2023
Produktens egenskaper Produktens egenskaper finska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 05-07-2017
Bipacksedel Bipacksedel svenska 27-09-2023
Produktens egenskaper Produktens egenskaper svenska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 05-07-2017
Bipacksedel Bipacksedel norska 27-09-2023
Produktens egenskaper Produktens egenskaper norska 27-09-2023
Bipacksedel Bipacksedel isländska 27-09-2023
Produktens egenskaper Produktens egenskaper isländska 27-09-2023
Bipacksedel Bipacksedel kroatiska 27-09-2023
Produktens egenskaper Produktens egenskaper kroatiska 27-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 05-07-2017

Sök varningar relaterade till denna produkt

Visa dokumenthistorik